Oryzon Genomics Financials
| ORY Stock | EUR 1.54 0.02 1.28% |
Oryzon |
Understanding current and past Oryzon Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Oryzon Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Oryzon Genomics' assets may result in an increase in income on the income statement.
Please note, the presentation of Oryzon Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oryzon Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oryzon Genomics' management manipulating its earnings.
Oryzon Genomics Stock Summary
Oryzon Genomics competes with ENCE Energa, Viscofan, Vidrala SA, and Ebro Foods. Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people.| Foreign Associate | Germany |
| Instrument | Spain Stock View All |
| Exchange | Madrid Exchange |
| ISIN | ES0167733015 |
| Business Address | Sant Ferran 74, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.oryzon.com |
| Phone | 34 93 515 13 13 |
| Currency | EUR - Euro |
You should never invest in Oryzon Genomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Oryzon Stock, because this is throwing your money away. Analyzing the key information contained in Oryzon Genomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Oryzon Genomics Key Financial Ratios
Oryzon Genomics' financial ratios allow both analysts and investors to convert raw data from Oryzon Genomics' financial statements into concise, actionable information that can be used to evaluate the performance of Oryzon Genomics over time and compare it to other companies across industries.| Return On Equity | -0.0685 | |||
| Return On Asset | -0.0419 | |||
| Target Price | 7.77 | |||
| Number Of Employees | 43 | |||
| Beta | 1.02 |
Oryzon Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oryzon Genomics's current stock value. Our valuation model uses many indicators to compare Oryzon Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oryzon Genomics competition to find correlations between indicators driving Oryzon Genomics's intrinsic value. More Info.Oryzon Genomics SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oryzon Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oryzon Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oryzon Genomics SA Systematic Risk
Oryzon Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oryzon Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Oryzon Genomics SA correlated with the market. If Beta is less than 0 Oryzon Genomics generally moves in the opposite direction as compared to the market. If Oryzon Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oryzon Genomics SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oryzon Genomics is generally in the same direction as the market. If Beta > 1 Oryzon Genomics moves generally in the same direction as, but more than the movement of the benchmark.
Oryzon Genomics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oryzon Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oryzon Genomics SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oryzon Genomics SA based on widely used predictive technical indicators. In general, we focus on analyzing Oryzon Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oryzon Genomics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 9.06 | |||
| Value At Risk | (2.16) | |||
| Potential Upside | 1.83 |
Complementary Tools for Oryzon Stock analysis
When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |